Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan

Phone: 03- 3817-5120 Fax: 03- 3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE
No. 07-06
March 1, 2007

Eisai Co., Ltd.

Eisai and Abbott Announce Amendment to Agreement for the Co-promotion of Rheumatoid Arthritis Drug HUMIRA® in Taiwan and Korea

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) today announced an amendment to the agreement with Abbott Biotechnology Ltd. (Headquarters: Bermuda President: Thomas C Freyman), concerning the sales of the rheumatoid arthritis drug HUMIRA® (generic name: adalimumab, fully human anti-TNF-α monoclonal antibody) in Taiwan and Korea. According to the revised agreement which was signed on February 28, 2007, Eisai's regional subsidiaries will purchase products from the Abbott's regional subsidiaries as the distributor in the regions, and both companies will co-promote the product under the brand name HUMIRA®. The sales will be booked to the Eisai's subsidiaries in Taiwan and Korea.

HUMIRA® is an antibody medication discovered and developed by Knoll AG (a company that Abbott acquired in 2001). The amendment follows the basic agreement signed in June 1999 for the joint development and marketing of the drug in Japan, Taiwan and Korea, in which the two companies originally agreed to a separate marketing and promotion scheme with their own separate brand names.

Currently HUMIRA® is approved for the treatment of rheumatoid arthritis and psoriatic arthritis in Taiwan and rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in Korea. The product launch in these regions is expected to be in April 2007, after completing the necessary preparation. In the U.S. and Europe, the product is marketed by Abbott.

Eisai believes that the new revised agreement for the co-promotion will ensure further contributions in increasing the benefits to the patients and their families by serving the needs of the people with rheumatoid arthritis with HUMIRA® in Taiwan and Korea.

[Please see the following note for the product information]

Contacts:

Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5036

<Note to Editor>

About HUMIRA®

- Generic Name: adalimumab (fully human anti-TNF-α monoclonal antibody)
- Approved Indication:

  Taiwan: rheumatoid arthritis and psoriatic arthritis

  Korea: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
- Dosage and Administration:

  Adalimumab 40mg is administered every other week as a single dose via subcutaneous injection for adult patients.

- **About TNF-α**

TNF (Tumor Necrosis Factor) is a cytokine that mediate interaction between the cells that are found to be vulnerary to tumor cells. TNF-α is produced by various cells such as macrophages, lymphocytes, vascular endothelial cells, and enhances inflammatory reaction or activates inflammatory cells.

- **About Monoclonal antibody**

A monoclonal antibody is an antibody produced by a single clone of cells. Monoclonal antibodies can be made in large amounts in the laboratory and are a cornerstone of immunology.